ArpaCoin (ARPAUSD): Yikes!

Play Episode

6min

Proactive - Interviews for investors

Candel Therapeutics shares positive survival data for investigational immunotherapy in NSCLC

Candel Therapeutics CEO Dr. Paul Peter Tak joined Steve Darling from Proactive to announce final survival data from a Phase 2a clinical trial evaluating the company’s investigational immunotherapy in patients with stage III/IV non-small cell lung cancer (NSCLC) who had an inadequate response to immune checkpoint inhibitor (ICI) treatment. The study reported a median overall survival (mOS) of 24.5 months in 46 evaluable patients who received two courses of the investigational therapy. In a subset of patients who had progressive disease at baseline despite ICI treatment, mOS was 21.5 months. Historically, similar patients receiving standard-of-care chemotherapy have had mOS between 9.8 and 11.8 months, with published studies rarely exceeding 12 months. With a median follow-up of 32.4 months, the data demonstrated long-term survival benefits, with 37% of patients who had progressive disease despite ICI therapy still alive two years after treatment. Based on these positive results, Candel Therapeutics will continue advancing the development program, including preparations for a potential registrational trial in patients with non-squamous histology NSCLC. The U.S. Food and Drug Administration (FDA) has previously granted Fast Track Designation for the investigational therapy in combination with an antiviral agent and ICI therapy for patients with stage III/IV NSCLC who are resistant to first-line PD-(L)1 inhibitors and do not have activating molecular driver mutations or have progressed on targeted therapy. These findings support the therapy’s potential as a new treatment option for NSCLC patients with limited alternatives. #proactiveinvestors #candeltherapeuticsinc #nasdaq #cadl #CancerTreatment #ViralTherapy #ProstateCancer #PancreaticCancer #Glioblastoma #PaulPeterTak #ClinicalTrials #BiotechNews #Immunotherapy #Oncology #CancerResearch

Proactive - Interviews for investors

Wrkr CEO on super compliance growth strategy

Wrkr Limited CEO Trent Lund talked with Proactive at the AIM's Small and Midcap Conference about the company’s strategy to simplify compliance through a deeply integrated digital platform. The ASX-listed company, trading under the ticker WRK, connects users, employers, and superannuation funds to streamline data accuracy and reduce friction in onboarding processes. “We do all the hard work and the heavy lifting so the business and the employee don’t have to,” said Lund. He explained that Wrkr verifies user credentials and automates data flows, reducing error and increasing trust. The system connects to major superannuation funds and payroll systems, holding accurate user information even during job transitions. Lund detailed Wrkr’s monetisation model, which aims to earn approximately $7 per user through microservices, including license checks and transactions. Current pilots, including one with major fund REST, are transitioning to production. Each super fund implementation takes about nine months and represents between $7 million and $14 million in annual annuity revenue once fully operational. Looking ahead, 2025 will be focused on large-scale implementation, with 2026 anticipated to generate higher consumption-based revenues. In 2027, Wrkr expects a significant uplift with the introduction of payday super legislation. #WrkrLimited #TrentLund #ASXWRK #Superannuation #ComplianceTech #FintechAustralia #PayrollIntegration #InvestorUpdate #PaydaySuper #DigitalTransformation #DataVerification #WorkforceAutomation

Proactive - Interviews for investors

MP Evans posts record 2024 results, eyes growth

MP Evans Group PLC (AIM:MPE) CEO Matthew Coulson takes Proactive's Stephen Gunnion through the company’s record results for 2024 and the strong start to 2025. MP Evans Group reported a robust financial performance in 2024, with Coulson confirming a record profit and a 66% increase in earnings per share. “It’s been a fantastic year for the group,” Coulson said, noting that high pricing supported the result, with prices averaging around $820 per tonne for the year. The company processed 1.6 million tonnes of crop in 2024, maintaining output despite weather-related challenges in Indonesia. Coulson highlighted this achievement in context: while Indonesia saw a slight national decline in crop yield, MP Evans sustained high volumes, reflecting operational resilience. Planting activity also continued across its operations, particularly in South Sumatra and East Kalimantan. The company expects to exceed 11,000 hectares planted at its Musi Rawas estate in early 2025, while its ABK site in East Kalimantan is set for more extensive development this year. Coulson also noted a milestone in sustainability, with over 250,000 tonnes of certified sustainable output processed across the company’s six mills in 2024. Looking ahead, he said 2025 had started positively, with pricing in the first two months averaging $870 per tonne, and the company is actively exploring acquisition opportunities. Visit Proactive’s YouTube channel for more insightful interviews. Don’t forget to like this video, subscribe to the channel, and enable notifications so you never miss an update. #MPEvans #PalmOil #Agribusiness #SustainableFarming #IndonesiaAgriculture #CropProduction #AgricultureInvestment #ESGInvesting #DividendStocks #CommoditiesMarket #ProactiveInvestors

Proactive - Interviews for investors

EBR Systems nears FDA approval for CRT pacemaker

EBR Systems Inc Senior Vice President Andrew Shute talked with Proactive at the AIM maSmall and Midcap Conference about the company’s upcoming FDA decision for its leadless CRT pacemaker system. The device is designed to treat heart failure and represents the only leadless option in a market currently dominated by three players—with no direct competitor. Shute said, “We've developed the world's only leadless pacemaker to treat heart failure. And we're on track to receive FDA approval within the next two and a half weeks.”* The product already holds FDA Breakthrough Device designation, and has shown strong clinical results, including a 16.4% reduction in left ventricular end systolic volume—well above the target goal of 9.3%. Shute outlined the company's go-to-market plan, emphasizing that reimbursement is expected to begin from October 1st under the NTAP and TPT schemes, enabling an ASP of USD 45,000. The company only needs to sell around 2,200 units annually to reach USD 100 million in revenue. “We’ve got no direct competition,” he said. He also highlighted the successful completion of the FDA’s pre-approval inspection with no observations—an uncommon achievement in the medical device industry. The device, supported by data published in JAMA Cardiology, was also featured at the Heart Rhythm Society meeting in 2023. During the interim, the US commercial team will establish purchasing agreements, prepare technology committee engagements, and begin physician training for a limited market release. #EBRSystems #MedicalDevices #HeartFailureTreatment #LeadlessPacemaker #CardiacTech #FDAApproval #CRTDevice #InvestingInHealthcare #BreakthroughDevice #MedTechInnovation #JAMACardiology #HeartRhythmSociety

Followers	121
Posts	8710
Boards Moderated	1
Alias Born	06/14/2006

Volume:	2,561,064
Day Range:	0.0223 - 0.02431
Bid:	0.02271
Ask:	0.02274
Last Trade Time:	12:41:06 PM EDT
Total Trades:	321

Volume
Day Range:
Bid Price
Ask Price
Last Trade Time:

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

ARPAUSD Detailed Quote

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Go Ad-Free